MktsMarkets

Protara Therapeutics, Inc.
NASDAQ: TARAKey statistics
TARA News
Stories mentioning TARA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 13,562 | 13,124 | 9,591 | 10,770 | 9,148 | 9,499 | 8,070 | 6,387 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 19,629 | 19,079 | 14,760 | 16,586 | 14,124 | 14,312 | 12,330 | 10,661 |
| Operating Income (Loss) | (19,629) | (19,079) | (14,760) | (16,586) | (14,124) | (14,312) | (12,330) | (10,661) |
| Interest Income | 1,847 | 1,523 | 1,502 | 1,626 | 1,729 | 1,156 | 1,111 | 1,148 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (17,782) | (17,307) | (13,258) | (14,960) | (11,914) | (12,769) | (11,219) | (9,513) |
| Earnings Per Share (Basic) | (0.31) | (0.40) | (0.31) | (0.35) | (0.29) | (0.62) | (0.50) | (0.45) |
| Earnings Per Share (Diluted) | (0.31) | (0.40) | (0.31) | (0.35) | (0.29) | (0.62) | (0.50) | (0.45) |
| Weighted Average Shares Outstanding (Basic) | 57,539 | 42,836 | 42,272 | 42,271 | 40,708 | 20,593 | 22,330 | 21,233 |
| Weighted Average Shares Outstanding (Diluted) | 57,539 | 42,836 | 42,272 | 42,271 | 40,708 | 20,593 | 22,330 | 21,233 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TARA
Protara Therapeutics, Inc. (NASDAQ: TARA) is a stock listed on the Nasdaq Stock Market under the ticker symbol TARA. It last traded at $2.44 (Nov 13, 2026, 9:41 AM ET), unchanged on the day. That gives Protara Therapeutics a market capitalisation of $150.2M.
Over the past 52 weeks TARA has traded between $2.09 and $7.82.
For the quarter ended Mar 31, 2026 it reported a net loss of $17.8M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$17.8M |
| Dec 31, 2025 | — | -$17.3M |
| Sep 30, 2025 | — | -$13.3M |
| Jun 30, 2025 | — | -$15.0M |
From Protara Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…